Paul Langley, B.Sc (Econ), M.A., Ph.D.
Dr Langley is an economist with a long standing interest in health technology assessment. His current research focuses on advocating a new start in HTA as the current analytical framework fails the standards for normal science and fundamental measurement. The focus must be on abandoning notions of single metric cost-effectiveness claims in favor of a valid profile of value claims to support empirical evaluation, ongoing disease area and therapeutic class reviews and outcomes based contracting.
Assessing value claims in formulary submissions